Submissions of new drug and biologic applications to the US Food and Drug Administration may have been depressed by the COVID-19 pandemic, but industry has far from given up, as a spate of recent announcements show.
Biogen Pharma’s Alzheimer’s disease therapy aducanumab stands out as the most controversial recent application. The cancer review center received...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?